MannKind Corp. (MNKD)

2.84 +0.09 (+3.27%) USD  |  NASDAQ  |  Apr 17, 16:00
2.875 +0.04 (+1.23%) After-Hours: 05:22
More

MannKind SG&A Expense (Quarterly) : 58.41M for Dec. 31, 2025

SG&A Expense (Quarterly) Chart

View SG&A Expense (Quarterly) for MNKD.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View SG&A Expense (Quarterly) Chart
Start Trial

Historical Data

View Historical Data
Start Trial

SG&A Expense (Quarterly) Range, Past 5 Years

View SG&A Expense (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

SG&A Expense (Quarterly) Benchmarks

View SG&A Expense (Quarterly) Benchmarks
Start Trial
United Therapeutics Corp. 160.80M
BioMarin Pharmaceutical, Inc. 446.21M
Amicus Therapeutics, Inc. 117.08M
Ionis Pharmaceuticals, Inc. 130.00M
Phathom Pharmaceuticals, Inc. 48.37M